Intra-Cellular Therapies (ITCI) Projected to Post Earnings on Friday

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) is expected to issue its Q4 2024 quarterly earnings data before the market opens on Friday, February 21st. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $205.08 million for the quarter.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The company had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. On average, analysts expect Intra-Cellular Therapies to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Intra-Cellular Therapies Stock Performance

ITCI stock traded up $0.06 during mid-day trading on Friday, hitting $128.60. The company had a trading volume of 1,263,662 shares, compared to its average volume of 2,149,492. The firm has a market cap of $13.67 billion, a PE ratio of -147.81 and a beta of 0.72. Intra-Cellular Therapies has a 12 month low of $62.78 and a 12 month high of $128.77. The stock's fifty day moving average price is $110.27 and its two-hundred day moving average price is $89.72.

Insiders Place Their Bets

In other news, CEO Sharon Mates sold 51,000 shares of the company's stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares of the company's stock, valued at approximately $91,834,228.20. This represents a 4.55 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.60% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ITCI. Needham & Company LLC reissued a "hold" rating on shares of Intra-Cellular Therapies in a research report on Friday. JPMorgan Chase & Co. boosted their price target on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an "overweight" rating in a research report on Monday, November 4th. Piper Sandler reissued a "neutral" rating and issued a $132.00 price target (up previously from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a report on Sunday, February 16th. They set a "hold" rating on the stock. Finally, Leerink Partnrs lowered shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Nine analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $103.62.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.